
Dongguk Life Science is moving to change its name to 'DK Luonix' and embark on a business structure restructuring aimed at expanding global operations.
The company plans to streamline its medical equipment (ME) division, which has continued to underperform due to the contraction of the diagnostic equipment market, and concentrate its resources on overseas operations and core pharmaceuticals to improve medium- to long-term profitability.
Dongguk Life Science announced on the 16th that it held a board meeting to strengthen its foundation for entering global markets and enhance business efficiency by pursuing a name change and restructuring of its business portfolio. An extraordinary general meeting of shareholders will be convened on the 11th of next month to partially amend the company's articles of incorporation in order to effectuate the name change.
The new name, DK Luonix, reflects the company's determination to expand its business scope into the global healthcare market, based on expertise accumulated in the field of diagnostic imaging medicine and a vertically integrated production foundation. The company plans to cultivate overseas operations as a new growth engine and concentrate management resources on core businesses, using the name change as an opportunity.
The company is currently proceeding with country-specific registration and regulatory approval procedures for its key products. It is also pursuing compliance with the European Union Good Manufacturing Practice (EU GMP) standards and the Certificate of Suitability to the monographs of the European Pharmacopoeia (CEP) related to magnetic resonance imaging (MRI) contrast agents.
The company plans to gradually expand sales regions and local partnerships, starting from countries where regulatory approvals are completed. Currently in the preparation stage for entering overseas markets, the company expects that results stemming from expanded overseas sales will appear gradually beginning in 2028.
The core of the business structure restructuring is the streamlining of the underperforming ME division. According to the company, following adjustments to insurance reimbursement rates for CT and MRI-related services in the second quarter of this year, the business environment in the diagnostic equipment market contracted, leading to continued revenue weakness in the ME division.
After reviewing the market environment and business profitability, Dongguk Life Science decided to streamline the ME division to reduce fixed costs and operational burdens.
The impact of the related business underperformance and structural restructuring was also reflected in the company's performance for the third quarter of this year.
The company plans to concentrate the management resources secured through the streamlining of the ME division on global operations and core pharmaceutical businesses.
Its goal is to allocate resources to high-growth potential businesses, restructure existing businesses based on market performance and profitability, and strengthen medium- to long-term competitiveness.
An official from Dongguk Life Science stated, "Overseas registration and regulatory approvals for key products are proceeding as planned, and we will cultivate global operations as a new growth engine for the company by expanding sales regions in the future."
The official added, "Taking the name change to DK Luonix as an opportunity, we will enhance our competitiveness in the global market and further strengthen the foundation for future growth."
The official continued, "We plan to concentrate resources on high-growth potential businesses while streamlining the ME division, where the market environment has contracted, to improve management efficiency and profitability." The official added, "Through the restructuring of our business portfolio, we will enhance medium- to long-term corporate valuation."